



**PATENT**  
**Attorney Dock t No. 082/US/PCT2/US**  
**00537/178002**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF:  
**CHRISTOPHE THURIEAU ET AL.**

APPLICATION NO.: **09/719,457**

FILED: **JUNE 13, 2001**


FOR: **IMIDAZOLYL DERIVATIVES**  
-----

Mail Stop: Non-Fee Amendment  
Commissioner of Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

EXAMINER: **LIU, HONG**  
ART UNIT: **1624**

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited by facsimile to (703) 746-5122 and with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: January 6, 2004

  
Dawn M. Janelle

Sir:

SUPPLEMENTAL REPLY UNDER 37 C.F.R. §1.116

In response to the Interview held January 6, 2004 in which the Examiner, Applicants respectfully request acceptance of the instant supplemental reply and entry of the amendments of the above-identified application as indicated below.

The present amendments follow the revised format procedure mandated in 68 Reg. 38611 published June 30, 2003.



Image AF

PATENT  
ATTORNEY DOCKET NO. 00537-178002 - 082/US/PCT2/US

Certificate of Mailing: Date of Deposit: 1/6/2004

I hereby certify under 37 C.F.R. 1.8(a) that this correspondence is being deposited via facsimile and with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dawn Janelle  
Printed name of person mailing correspondence

Dawn M Janelle  
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: THURIEAU, Christophe et al.  
Serial No.: 09/719,457  
Filed: June 13, 2001  
Title: IMIDAZOLYL DERIVATIVES

Art Unit: 1624  
Examiner: LUI, Hong

Mail Stop: Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

To Whom It May Concern:

TRANSMITTAL LETTER AND FEE AUTHORIZATION

Transmitted herewith is a Reply under 37 C.F.R. §1.116 with a Certificate of Mailing noted thereon, and an acknowledgement postcard.

No fee is believed to be due for this submission. However, Applicant(s) hereby authorize the Commissioner for Patents to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. A duplicate copy of this letter is enclosed.

Date: 1-6-2004

Respectfully submitted,

Alan F. Feeney

Alan F. Feeney  
Attorney for Applicant(s)  
Reg. No. 43,609

Biomeasure, Incorporated  
27 Maple Street  
Milford, MA 01757-3650  
(508) 478-0144



## TELEFAX

**DATE:** January 6, 2004

**TO:** U.S. Patent & Trademark Office  
Examiner: LIU, Hong  
Fax: (703) 746-5122

**FROM:** Alan F. Feeney, Esq.  
Biomeasure, Incorporated  
Milford, Mass., U.S.A.

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited by Facsimile on the date indicated below and is addressed to the Commissioner of Patents, Fax no. 703 746-5122  
Date of Deposit: 1/6/04  
Dawn Janelle *Dawn Janelle*

**SUBJECT:** Reply under 1.116 (5  
Pages)  
Transmittal Letter (1 page)  
Docket No.: 00537-178002  
Serial No.: 09/719,457  
Title: Imidazolyl Derivatives

**PAGES:** 7 (including cover page)

### **COMMENTS:**

"This telefacsimile communication is intended only for the use of the person(s) or entity named above and contains information that is legally privileged and confidential. If the person who receives this communication is not the person(s) or entity named above, or an employee or agent responsible for delivering it to them, you are hereby notified that any dissemination, distribution, copying or other use of this communication is strictly prohibited. Anyone who receives this communication in error is requested to notify the sender immediately by telephone, and to return the original telefacsimile communication to the sender at the above address by the U.S. mail. Thank you"